Burning Rock Dx
Biotechnology Research • 
Irvine, California, United States • 21-50 Employees
Company overview
| Headquarters | 121 Innovation Dr, Irvine, California 92617, US |
| Phone number | +864006897600 |
| Website | |
| NAICS | 541714 |
| Keywords | Biotechnology, Oncology, Biopharma, Pharmaceutical, Clinical Trial, Companion Diagnostics, Precision Medicine, NGS, IVD, Next-Generation Sequencing, Ngs Panels, Neoantigens, Cdx, Tumor Testing |
| Founded | 2014 |
| Employees | 21-50 |
| Socials |
Key Contacts at Burning Rock Dx
Liliang Jin
Associate Director Of Business Development
Shawn Amistade
Director Of Business Development
Burning Rock Dx Email Formats
Burning Rock Dx uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@brbiotech.com), used 52.9% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@brbiotech.com | 52.9% |
{first initial}.{last name} | j.doe@brbiotech.com | 47.1% |
About Burning Rock Dx
Burning Rock Biotech Limited (NASDAQ: BNR ) Burning Rock Biotech is a global diagnostics company specializing in next-generation sequencing (NGS) technology for precision oncology. Our Mission Guard Life via Science Our Vision To Become a New Pillar in the International Healthcare Industry What We Offer We provide solutions throughout the precision oncology development cycle, including: NGS-Based Assays: Comprehensive portfolio for tissue and blood samples In-House Database: Facilitating clinical trial studies and research Pharmaceutical Partner Services: Genomic data solutions Clinical trial solutions Precision patient recruitment Companion diagnostics (CDx) development and commercialization Global Operations With CLIA/CAP laboratories in China and the United States, we support global clinical trials. Our achievements include: 2 NMPA-Approved IVD Kits 4 Assays with CE Marking 1 MHLW-Approved CDx System Breakthrough Device Designation (BDD) from both the US FDA and China NMPA for multi-cancer detection blood tests Leveraging advanced NGS technology and extensive pharmaceutical partnerships, Burning Rock is dedicated to advancing precision oncology worldwide.
Burning Rock Dx revenue & valuation
| Annual revenue | $3,678,865 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $11,800,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Burning Rock Dx has 16 employees across 8 departments.
Departments
Number of employees
Funding Data
Burning Rock Dx has never raised funding before.
Australia
United Kingdom
Frequently asked questions
4.8
40,000 users
